Author(s): Teixeira, Marta Sofia Vilela Barreira ; Castanheira, Elisabete M. S. ; Carvalho, M. Alice
Date: 2024
Persistent ID: https://hdl.handle.net/1822/95067
Origin: RepositóriUM - Universidade do Minho
Subject(s): Anticancer drug; Liposomes; Albumin nanoparticles
Cancer is a threat for humankind [1], and the scientific community has been fighting against this disease, developing new strategies and new potential chemotherapeutic agents.[2,3] Many of the drugs already used in chemotherapy (or under development) have poor water solubility and, therefore, cannot reach the targets efficiently.[4] The development of nanoformulations is a strategy followed to solve solubility issues and other problems related to pharmacokinetics.[5] Different nanosystems have been studied to carry these poorly water-soluble drugs, such as liposomes and albumin‐based nanosystems, two major classes of organic nanocarriers with formulations already approved by the U.S. Food and Drug Administration (FDA) for cancer therapeutics. [6,7] In our research group, a Hit compound was discovered that exhibits high anticancer activity (IC50 = 0.8 µM) against the colorectal cancer cell line (HCT-116) and low toxicity to normal cells, but displayed low water solubility, which was an obstacle to progress to in vivo studies. In this work, we developed liposomal and albumin‐based nanoformulations loaded with the hit compound. The results of drug-loading efficiency, release kinetics and stability will be presented.
